Table 4.
HR-HPV and clinicopathological features in Egyptian women with BC.
| HR-HPV pos (n = 16) | HPV neg (n = 56) | P value | |
|---|---|---|---|
| Stage | .5 | ||
| Early (I and II) | 11 (68.75%)a | 34 (60.7%) | |
| Advanced (III and IV) | 4 (25%) | 19 (33.9%) | |
| Unknown | 1 (6.25%) | 3 (5.4%) | |
| Histopathology | .13 | ||
| Invasive duct carcinoma | 9 (56.25%) | 45 (80.4%) | |
| Other pathologic types | 7 (43.75%) | 11 (19.6%) | |
| Size (cm) | .88 | ||
| <2 | 3 (18.75%) | 8 (14.3%) | |
| 2-5 | 11 (68.75%) | 43 (76.8%) | |
| >5 | 1 (6.25%) | 5 (8.9%) | |
| Unknown | 1 (6.25%) | 0 | |
| Grade | .9 | ||
| I and II | 12 (75%) | 44 (78.6%) | |
| III and IV | 3 (18.75%) | 12 (21.4%) | |
| Unknown | 1 (6.25%) | 0 | |
| Lymph node metastasis | .77 | ||
| Negative | 7 (43.75%) | 28 (50%) | |
| Positive | 8 (50%) | 27 (48.2%) | |
| Unknown | 1 (6.25%) | 1 (1.8%) |
Abbreviations: BC, breast cancer; HR-HPV, high-risk human papilloma virus.
a
Numbers in parenthesis represent the percent.